研究者業績

清野 宏

キヨノ ヒロシ  (Hiroshi Kiyono)

基本情報

所属
千葉大学 未来医療教育研究機構 特任教授 (卓越教授)
学位
医学博士

J-GLOBAL ID
200901090720634306
researchmap会員ID
0000021773

外部リンク

Dr. Kiyono obtained his dental degree (D.D.S.) from Nihon University, and Ph. D. from the University of Alabama at Birmingham (UAB). His background as a dentist combined with extensive research experience in the field of Mucosal Immunology at UAB, Max-Planck Institute, Osaka University and now, the University of Tokyo make him exceptionally well qualified to lead the current and future directions of mucosal immunology and mucosal vaccine. To reflect his scientific contribution, he has been listed in ISI Highly Cited Researchers’ List since 2005. He is the past President of Society for Mucosal Immunology. He received of several prestigious awards including NIH New Investigator Research Award, NIH Research Career Development Award, The Japanese Society for Vaccinology Takahashi Award, and Hideyo Noguchi Memorial Medical Science Award. He has a total of 422 publications in peer review journals and edited a total of 20 books. He is currently Dean, the Institute of Medical Science, the University of Tokyo.

論文

 379
  • Yoshikazu Yuki, Shiho Kurokawa, Kotomi Sugiura, Koji Kashima, Shinichi Maruyama, Tomoyuki Yamanoue, Ayaka Honma, Mio Mejima, Natsumi Takeyama, Masaharu Kuroda, Hiroko Kozuka-Hata, Masaaki Oyama, Takehiro Masumura, Rika Nakahashi-Ouchida, Kohtaro Fujihashi, Takashi Hiraizumi, Eiji Goto, Hiroshi Kiyono
    Frontiers in Plant Science 15 2024年3月15日  
    We previously established the selection-marker-free rice-based oral cholera vaccine (MucoRice-CTB) line 51A for human use by Agrobacterium-mediated co-transformation and conducted a double-blind, randomized, placebo-controlled phase I trial in Japan and the United States. Although MucoRice-CTB 51A was acceptably safe and well tolerated by healthy Japanese and U.S. subjects and induced CTB-specific antibodies neutralizing cholera toxin secreted by Vibrio cholerae, we were limited to a 6-g cohort in the U.S. trial because of insufficient production of MucoRice-CTB. Since MucoRice-CTB 51A did not grow in sunlight, we re-examined the previously established marker-free lines and selected MucoRice-CTB line 19A. Southern blot analysis of line 19A showed a single copy of the CTB gene. We resequenced the whole genome and detected the transgene in an intergenic region in chromosome 1. After establishing a master seed bank of MucoRice-CTB line 19A, we established a hydroponic production facility with LED lighting to reduce electricity consumption and to increase production capacity for clinical trials. Shotgun MS/MS proteomics analysis of MucoRice-CTB 19A showed low levels of α-amylase/trypsin inhibitor-like proteins (major rice allergens), which was consistent with the data for line 51A. We also demonstrated that MucoRice-CTB 19A had high oral immunogenicity and induced protective immunity against cholera toxin challenge in mice. These results indicate that MucoRice-CTB 19A is a suitable oral cholera vaccine candidate for Phase I and II clinical trials in humans, including a V. cholerae challenge study.
  • Zhongwei Zhang, Izumi Tanaka, Rika Nakahashi-Ouchida, Peter B Ernst, Hiroshi Kiyono, Yosuke Kurashima
    Seminars in immunopathology 2024年1月3日  
    Glycoprotein 2 (GP2) is a widely distributed protein in the digestive tract, contributing to mucosal barrier maintenance, immune homeostasis, and antigen-specific immune response, while also being linked to inflammatory bowel disease (IBD) pathogenesis. This review sheds light on the extensive distribution of GP2 within the gastrointestinal tract and its intricate interplay with the immune system. Furthermore, the significance of GP2 autoantibodies in diagnosing and categorizing IBD is underscored, alongside the promising therapeutic avenues for modulating GP2 to regulate immunity and maintain mucosal balance.
  • Xiao Sun, Koji Hosomi, Atsushi Shimoyama, Ken Yoshii, Azusa Saika, Haruki Yamaura, Takahiro Nagatake, Hiroshi Kiyono, Koichi Fukase, Jun Kunisawa
    International Immunology 2023年11月25日  
    Abstract We previously demonstrated that Alcaligenes-derived lipid A (ALA), which is produced from an intestinal lymphoid tissue-resident commensal bacterium, is an effective adjuvant for inducing antigen-specific immune responses. To understand the immunologic characteristics of ALA as a vaccine adjuvant, we here compared the adjuvant activity of ALA with that of a licensed adjuvant (monophosphoryl lipid A, MPLA) in mice. Although the adjuvant activity of ALA was only slightly greater than that of MPLA for subcutaneous immunization, ALA induced significantly greater IgA antibody production than did MPLA during nasal immunization. Regarding the underlying mechanism, ALA increased and activated CD11b+ CD103− CD11c+ dendritic cells in the nasal tissue by stimulating chemokine responses. These findings revealed the superiority of ALA as a mucosal adjuvant due to the unique immunologic functions of ALA in nasal tissue.
  • Naomi Matsumoto, Shiho Kurokawa, Shigeyuki Tamiya, Yutaka Nakamura, Naomi Sakon, Shoko Okitsu, Hiroshi Ushijima, Yoshikazu Yuki, Hiroshi Kiyono, Shintaro Sato
    Viruses 15(9) 2023年9月15日  
    Sapoviruses, like noroviruses, are single-stranded positive-sense RNA viruses classified in the family Caliciviridae and are recognized as a causative pathogen of diarrhea in infants and the elderly. Like human norovirus, human sapovirus (HuSaV) has long been difficult to replicate in vitro. Recently, it has been reported that HuSaV can be replicated in vitro by using intestinal epithelial cells (IECs) derived from human tissues and cell lines derived from testicular and duodenal cancers. In this study, we report that multiple genotypes of HuSaV can sufficiently infect and replicate in human-induced pluripotent stem cell-derived IECs. We also show that this HuSaV replication system can be used to investigate the conditions for inactivation of HuSaV by heat and alcohol, and the effects of virus neutralization of antisera obtained by immunization with vaccine antigens, under conditions closer to the living environment. The results of this study confirm that HuSaV can also infect and replicate in human normal IECs regardless of their origin and are expected to contribute to future virological studies.
  • Yoshikazu Yuki, Norihiro Harada, Shin-Ichi Sawada, Yohei Uchida, Rika Nakahashi-Ouchida, Hiromi Mori, Tomoyuki Yamanoue, Tomonori Machita, Masakatsu Kanazawa, Dai Fukumoto, Hiroyuki Ohba, Takashi Miyazaki, Kazunari Akiyoshi, Kohtaro Fujihashi, Hiroshi Kiyono
    Vaccine 41(34) 4941-4949 2023年7月31日  
    Cationic cholesteryl-group-bearing pullulan nanogel (cCHP-nanogel) is an effective drug-delivery system for nasal vaccines. However, cCHP-nanogel-based nasal vaccines might access the central nervous system due to its close proximity via the olfactory bulb in the nasal cavity. Using real-time quantitative tracking of the nanogel-based nasal botulinum neurotoxin and pneumococcal vaccines, we previously confirmed the lack of deposition of vaccine antigen in the cerebrum or olfactory bulbs of mice and non-human primates (NHPs), rhesus macaques. Here, we used positron emission tomography to investigate the biodistribution of the drug-delivery system itself, cCHP-nanogel after mice and NHPs were nasally administered with 18F-labeled cCHP nanogel. The results generated by the PET analysis of rhesus macaques were consistent with the direct counting of radioactivity due to 18F or 111In in dissected mouse tissues. Thus, no depositions of cCHP-nanogel were noted in the cerebrum, olfactory bulbs, or eyes of both species after nasal administration of the radiolabeled cCHP-nanogel compound. Our findings confirm the safe biodistribution of the cCHP-nanogel-based nasal vaccine delivery system in mice and NHPs.

MISC

 630
  • 楠美昭則, 藤橋浩太郎, 広井隆親, 山本正文, 木村博人, 清野宏
    日本免疫学会総会・学術集会記録 26 387 1996年10月  
  • M Shimaoka, T Hiroi, N Taenaka, H Kiyono, Yoshiya, I
    ANESTHESIOLOGY 85(3A) A297-A297 1996年9月  
  • M Sugimoto, M Shimaoka, N Taenaka, H Kiyono, Yoshiya, I
    ANESTHESIOLOGY 85(3A) A207-A207 1996年9月  
  • 廣井 隆親, 清野 宏
    口腔・咽頭科 = Stomato-pharyngology 8(3) 291-301 1996年6月1日  
  • 藤橋 浩太郎, 清野 宏
    医学のあゆみ 177(5) 393-398 1996年5月4日  
  • Raymond J. Jackson, Kohtaro Fujihashi, Hiroshi Kiyono, Jerry R. McGhee
    Journal of Immunological Methods 190(2) 189-197 1996年4月19日  
    We have directly compared enzyme-linked immunoassays (ELlSAs) with bioluminescent immunoassays employing derivatives of the bioluminescent molecule aequorin, and have shown that detection of mucosal and serum antibodies is considerably more sensitive when detected by luminometry. Luminometry is based upon counting photons of light via phototubes and is generally similar to scintillation spectrometry. Current commercial luminometric technology employs a phototube which is most efficient for light emission in the 400-420 nm wavelength range. For this reason, we have chosen the bioluminescent molecule, aequorin, which upon the addition of Ca2+ undergoes a conformational change resulting in the emission of blue light at 469 nm. The high quantum yield is reflected by the fact that addition of Ca2+ to 1 ng of recombinant streptaequorin, a covalent conjugate of streptavidin and aequorin, resulted in the production of 7 x 108 relative light units. In this study, we show the superior sensitivity of biotin-streptaequorin when directly compared with biotin-streptavidin linked horseradish peroxidase commonly used for ELISA. For example, mice orally immunized once with cholera toxin (CT) did not exhibit detectable fecal IgA antibodies as determined by ELISA, whereas use of streptaequorin and the bioluminescent immunoassay revealed fecal IgA anti-CT-B subunit antibody titers of 1 : 24500. In addition, no detectable anti-CT-B antibodies were noted in saliva samples by ELISA 7 days following oral immunization with CT, while IgA endpoint titers could be extrapolated to 1: 393000. The 21 day fecal IgA anti-CT-B titers were 1: 512 by ELISA, whereas titers determined by luminometry reached 1 : 107 when Neutralite avidin and biotinylated aequorin were employed. In general, the bioluminescent immunoassay was &gt 104-fold more sensitive when compared with ELISA for detection of mucosal and serum antigen- and isotype-specific antibody responses. Thus, the bioluminescent immunoassay is a more sensitive assay for detection of antibodies in dilute extemal secretions.
  • Raymond J. Jackson, Kohtaro Fujihashi, Hiroshi Kiyono, Jerry R. McGhee
    Journal of Immunological Methods 190(2) 189-197 1996年4月19日  
    We have directly compared enzyme-linked immunoassays (ELlSAs) with bioluminescent immunoassays employing derivatives of the bioluminescent molecule aequorin, and have shown that detection of mucosal and serum antibodies is considerably more sensitive when detected by luminometry. Luminometry is based upon counting photons of light via phototubes and is generally similar to scintillation spectrometry. Current commercial luminometric technology employs a phototube which is most efficient for light emission in the 400-420 nm wavelength range. For this reason, we have chosen the bioluminescent molecule, aequorin, which upon the addition of Ca2+ undergoes a conformational change resulting in the emission of blue light at 469 nm. The high quantum yield is reflected by the fact that addition of Ca2+ to 1 ng of recombinant streptaequorin, a covalent conjugate of streptavidin and aequorin, resulted in the production of 7 x 108 relative light units. In this study, we show the superior sensitivity of biotin-streptaequorin when directly compared with biotin-streptavidin linked horseradish peroxidase commonly used for ELISA. For example, mice orally immunized once with cholera toxin (CT) did not exhibit detectable fecal IgA antibodies as determined by ELISA, whereas use of streptaequorin and the bioluminescent immunoassay revealed fecal IgA anti-CT-B subunit antibody titers of 1 : 24500. In addition, no detectable anti-CT-B antibodies were noted in saliva samples by ELISA 7 days following oral immunization with CT, while IgA endpoint titers could be extrapolated to 1: 393000. The 21 day fecal IgA anti-CT-B titers were 1: 512 by ELISA, whereas titers determined by luminometry reached 1 : 107 when Neutralite avidin and biotinylated aequorin were employed. In general, the bioluminescent immunoassay was &gt 104-fold more sensitive when compared with ELISA for detection of mucosal and serum antigen- and isotype-specific antibody responses. Thus, the bioluminescent immunoassay is a more sensitive assay for detection of antibodies in dilute extemal secretions.
  • Kohtaro Fujihashi, Shigetada Kawabata, Takachika Hiroi, Masafumi Yamamoto, Jerry R. McGhee, Shin-Ichi Nishikawa, Hiroshi Kiyono
    Proceedings of the National Academy of Sciences of the United States of America 93(8) 3613-3618 1996年4月16日  
    In this study, we describe the interaction between cytokine and cytokine receptor (R) for the activation and proliferation of γδ T-cell receptor. positive T cells (γδ T cells). γδ T cells isolated from murine intestinal intraepithelial lymphocytes (IELs) were separated into γδ(Dim) and γδ(Bright) fractions according to the intensity of γδ T-cell receptor expression. The γδ(Dim) T cells express low levels of IL-2R and IL-7R as shown by flow cytometry and reverse transcriptase-PCR analysis, whereas γδ(Bright) T cells did not express either receptor. Our study also revealed that recombinant murine (rm)IL-2 and rmIL-7 reciprocally induced high expressions of IL-7R and IL-2R, respectively, on γδ(Dim) T cells but not on γδ(Bright) IELs. Thus, treatment of γδ(Dim) T cells with rmIL-2 and rmIL- 7 resulted in high proliferative responses, whereas γδ(Bright) T cells did not respond to these two cytokines. The sources of these two cytokines for γδ(Dim) T cells were neighboring epithelial cells (IL-7) and αβ IELs (IL- 2 and IL-7). Cytokine signaling by IL-2 and IL-7 from αβ T cells and epithelial cells was necessary for the expression of IL-7R and IL-2R, respectively, on a subset of γδ T cells (e.g., γδ(Dim) T cells) in mucosa-associated tissue for subsequent activation and cell division.
  • Kohtaro Fujihashi, Shigetada Kawabata, Takachika Hiroi, Masafumi Yamamoto, Jerry R. McGhee, Shin-Ichi Nishikawa, Hiroshi Kiyono
    Proceedings of the National Academy of Sciences of the United States of America 93(8) 3613-3618 1996年4月16日  
    In this study, we describe the interaction between cytokine and cytokine receptor (R) for the activation and proliferation of γδ T-cell receptor. positive T cells (γδ T cells). γδ T cells isolated from murine intestinal intraepithelial lymphocytes (IELs) were separated into γδ(Dim) and γδ(Bright) fractions according to the intensity of γδ T-cell receptor expression. The γδ(Dim) T cells express low levels of IL-2R and IL-7R as shown by flow cytometry and reverse transcriptase-PCR analysis, whereas γδ(Bright) T cells did not express either receptor. Our study also revealed that recombinant murine (rm)IL-2 and rmIL-7 reciprocally induced high expressions of IL-7R and IL-2R, respectively, on γδ(Dim) T cells but not on γδ(Bright) IELs. Thus, treatment of γδ(Dim) T cells with rmIL-2 and rmIL- 7 resulted in high proliferative responses, whereas γδ(Bright) T cells did not respond to these two cytokines. The sources of these two cytokines for γδ(Dim) T cells were neighboring epithelial cells (IL-7) and αβ IELs (IL- 2 and IL-7). Cytokine signaling by IL-2 and IL-7 from αβ T cells and epithelial cells was necessary for the expression of IL-7R and IL-2R, respectively, on a subset of γδ T cells (e.g., γδ(Dim) T cells) in mucosa-associated tissue for subsequent activation and cell division.
  • PR Harris, HC Weber, CM Wilcox, S Kawabata, H Kiyono, RT Jensen, PD Smith
    GASTROENTEROLOGY 110(4) A922-A922 1996年4月  
  • K Fujihashi, McGhee, JR, M Kweon, MD Cooper, S Tonegawa, Takahashi, I, T Hiroi, J Mestecky, H Kiyono
    FASEB JOURNAL 10(6) 2529-2529 1996年4月  
  • M Kweon, K Fujihashi, M Yamamoto, JL VanCott, McGhee, JR, H Kiyono
    FASEB JOURNAL 10(6) 167-167 1996年4月  
  • Y Shimpuku, K Morishita, M Yamamoto, K Fujihashi, McGhee, JR, S Otake, H Kiyono
    FASEB JOURNAL 10(6) 1102-1102 1996年4月  
  • CM Wilcox, PR Harris, S Kawabata, H Kiyono, PD Smith
    GASTROENTEROLOGY 110(4) A1044-A1044 1996年4月  
  • A Kusumi, K Fujihashi, T Hiroi, M Yamamoto, McGhee, JR, H Kiyono
    FASEB JOURNAL 10(6) 1278-1278 1996年4月  
  • HH Nguyen, Z Moldoveanu, M Novak, H Kiyono, JM McGhee, J Mestecky
    FASEB JOURNAL 10(6) 1832-1832 1996年4月  
  • DW Pascual, DM Hone, S Hall, FW vanGinkel, M Yamamoto, K Fujihashi, RJ Powell, S Wu, JL VanCott, H Kiyono, McGhee, JR
    FASEB JOURNAL 10(6) 480-480 1996年4月  
  • Y Yuki, K Fujihashi, M Yamamoto, McGhee, JR, H Kiyono
    FASEB JOURNAL 10(6) 1042-1042 1996年4月  
  • S Yamamoto, H Kurazono, M Yamamoto, M Yamamoto, R Jackson, K Fujihashi, H Kiyono, Y Takeda, McGhee, JR
    FASEB JOURNAL 10(6) 1103-1103 1996年4月  
  • PN Boyaka, K Fujihashi, McGhee, JR, S Kawabata, H Kiyono
    FASEB JOURNAL 10(6) 2100-2100 1996年4月  
  • FW vanGinkel, DW Pascual, C Liu, RA Frizzell, H Kiyono, McGhee, JR
    FASEB JOURNAL 10(6) 1104-1104 1996年4月  
  • Takahashi, I, H Kiyono, S Hamada
    FASEB JOURNAL 10(6) 462-462 1996年4月  
  • M Marinaro, PN Boyaka, RJ Jackson, FD Finkelman, MK Gately, H Kiyono, McGhee, JR
    FASEB JOURNAL 10(6) 212-212 1996年4月  
  • K Imaoka, M Kubota, H Kiyono, C Miller, S Kawabata, K Fujihashi, McGhee, JR
    FASEB JOURNAL 10(6) 1844-1844 1996年4月  
  • JL VanCott, SN Chatfield, D Hone, DW Pascual, E Hohmann, H Kiyono, McGhee, JR
    FASEB JOURNAL 10(6) 114-114 1996年4月  
  • M Kubota, McGhee, JR, C Miller, K Imaoka, S Kawabata, K Fujihashi, T Lehner, H Kiyono
    FASEB JOURNAL 10(6) 361-361 1996年4月  
  • 藤橋 浩太郎, 清野 宏
    最新医学 51(4) 433-441 1996年4月  
  • J. Exp. Med, 183 : 1929-1935. 183(4) 1929-1935 1996年4月1日  
  • Kohtaro Fujihashi, Jerry R. McGhee, Mi-Na Kweon, Max D. Cooper, Susumu Tonegawa, Ichiro Takahashi, Takachika Hiroi, Jiri Mestecky, Hiroshi Kiyono
    Journal of Experimental Medicine 183(4) 1929-1935 1996年4月1日  
    Mucosal tissues of mice are enriched in T cells that express the γ/δ T cell receptor. Since the function of these cells remains unclear, we have compared mucosal immune responses in γ/δ T cell receptor-deficient (TCRδ(- /-)) mice versus control mice of the same genetic background. The frequency of intestinal immunoglobulin (Ig) A plasma cells as well as IgA levels in serum, bile, saliva, and fecal samples were markedly reduced in TCRδ(-/-) mice. The TCRδ(-/-) mice produced much lower levels of IgA antibodies when immunized orally with a vaccine of tetanus toxoid plus cholera toxin as adjuvant. Conversely, the antigen-specific IgM and IgG antibody responses were comparable to orally immunized control mice. Direct assessment of the cells forming antibodies against the tetanus toxoid and cholera toxin antigens indicated that significantly lower numbers of IgA antibody-producing cells were present in the intestinal lamina propria and Peyer's patches of TCR(-/-) mice compared with the orally immunized control mice. The selective reduction of IgA responses to ingested antigens in the absence of γ/δ T cells suggests a specialized role for γ/δ T cells in mucosal immunity.
  • Raymond J. Jackson, Mariarosaria Marinaro, John L. VanCott, Masafumi Yamamoto, Nobuo Okahashi, Kohtaro Fujihashi, Hiroshi Kiyono, Steven N. Chatfield, Jerry R. McGhee
    Journal of Biotechnology 44(1-3) 209-216 1996年1月26日  
    The mechanisms which regulate mucosal IgA responses to orally administered protein vaccines are not yet fully elucidated. We have used two delivery systems, soluble tetanus toxoid (TT) with the mucosal adjuvant cholera toxin (CT) and recombinant Salmonella expressing Tox C, a fragment of TT, to assess the nature of CD4+ T helper (Th) cells and derived cytokines which support mucosal IgA responses in both normal and cytokine knockout (interferon gamma knockout IFN-γ(-/-) and IL-4(-/-)) mice. Our results provide important new information regarding Th cell and cytokine regulation of mucosal IgA responses. Whereas TT coadministered with CT induces predominant TT-specific Th2-type responses, rSalmonella delivery of Tox C induced dominant Th1-type responses along with synthesis of the Th2-cytokine L-10. Both vaccine regimen elicited high levels of mucosal S-IgA and IL-6 production by macrophages. Further, oral immunization of IFN-γ(-/-) and IL-4(-/-) mice with rSalmonella Tox C also induced macrophage-derived IL-6 and Th2-derived IL-10 as well as S-IgA responses, suggesting that IFN-γ from Th1-type cells as well as traditional Th2 cells producing IL-4 and IL-5 are not essential for mucosal IgA responses. Rather, induction of second level Th2 cells producing IL-10 together with high levels of IL-6 from other cell sources may be sufficient for mucosal IgA responses in the absence of traditional Th2 cells. These studies were facilitated by the development of a sensitive new luminometry assay which allowed detection of cytokines and cell surface molecules which are below the levels of detection by current solid phase assays.
  • Raymond J. Jackson, Mariarosaria Marinaro, John L. VanCott, Masafumi Yamamoto, Nobuo Okahashi, Kohtaro Fujihashi, Hiroshi Kiyono, Steven N. Chatfield, Jerry R. McGhee
    Journal of Biotechnology 44(1-3) 209-216 1996年1月26日  
    The mechanisms which regulate mucosal IgA responses to orally administered protein vaccines are not yet fully elucidated. We have used two delivery systems, soluble tetanus toxoid (TT) with the mucosal adjuvant cholera toxin (CT) and recombinant Salmonella expressing Tox C, a fragment of TT, to assess the nature of CD4+ T helper (Th) cells and derived cytokines which support mucosal IgA responses in both normal and cytokine knockout (interferon gamma knockout IFN-γ(-/-) and IL-4(-/-)) mice. Our results provide important new information regarding Th cell and cytokine regulation of mucosal IgA responses. Whereas TT coadministered with CT induces predominant TT-specific Th2-type responses, rSalmonella delivery of Tox C induced dominant Th1-type responses along with synthesis of the Th2-cytokine L-10. Both vaccine regimen elicited high levels of mucosal S-IgA and IL-6 production by macrophages. Further, oral immunization of IFN-γ(-/-) and IL-4(-/-) mice with rSalmonella Tox C also induced macrophage-derived IL-6 and Th2-derived IL-10 as well as S-IgA responses, suggesting that IFN-γ from Th1-type cells as well as traditional Th2 cells producing IL-4 and IL-5 are not essential for mucosal IgA responses. Rather, induction of second level Th2 cells producing IL-10 together with high levels of IL-6 from other cell sources may be sufficient for mucosal IgA responses in the absence of traditional Th2 cells. These studies were facilitated by the development of a sensitive new luminometry assay which allowed detection of cytokines and cell surface molecules which are below the levels of detection by current solid phase assays.
  • SD Simpson, DP Snider, LA Zettel, H Kiyono, JC Unkeless, PB Ernst
    CELLULAR IMMUNOLOGY 167(1) 122-128 1996年1月  
    IgA and IgG binding factors (BF) can be found in the supernatant (T-h SUP) Of cultures containing macrophages and CD4(+) T cells stimulated with particulate antigens such as SRBC. Previous work indicated that these IgBF, when mixed with normal serum immunoglobulin, could block the activity of suppressor T cells (T-s) and allow IgA and IgG PFC responses in vibro. We present serologic and functional evidence that IgABF and IgGBF in T-h sup are soluble Fc alpha R and Fc gamma RII(or III), respectively. Th sup adsorbed on affinity columns containing anti-Fc gamma RII/III mAb or murine IgG failed to augment IgG PFC responses. Material eluted from either the IgG or anti-Fc gamma RII/ III columns could be added back, interchangeably, to the adsorbed T-h sup and restore IgG PFC. Recombinant murine Fc gamma RII (rFc gamma RII), added to the same adsorbed T-h sup at 0.01 to 0.5 ng/ml, resulted in a similar augmentation of IgG PFC. Interestingly, much higher concentrations of rFc gamma RII (10-100 ng/ ml) could not, augment IgG; PPC responses. Protein dot blots showed that T-h sup and the eluted material from murine IgG: columns contained structures reactive with the Fc gamma RII/III mAb. Similar studies using purified Fc alpha R revealed that IgABF eluted from IgA or anti-Fc alpha R columns was in fact Fc alpha R. Cross-adsorption studies indicated clearly that the IgGBF (Fc gamma RII/III) and the IgABF (FC alpha R) were separate molecules produced in the same T-h sup and that each regulated their respective Ig isotype independently. Thus, cultures of splenic macrophage and CD4(+) T cells, in the presence of particulate antigens such as SRBC, generate both Fc gamma RII/III and Fc alpha R. This soluble FcR in combination with serum Ig act to block isotype-specific T-s cells at low concentration in vitro. (C) 1996 Academic Press, Inc.
  • John L. VanCott, Toshiya Kobayashi, Masafumi Yamamoto, Subramonia Pillai, Jerry R. McGhee, Hiroshi Kiyono
    Vaccine 14(5) 392-398 1996年  
    Liposome and cholera toxin (CT) are considered to be effective antigen delivery vehicles and adjuvants for mucosal vaccines. The effect of these antigen delivery systems on adjuvant responses to mucosally administered pneumococcal polysaccharide (Pnup) was investigated in this study. Both mucosal (e.g oral) and systemic (IP) immunization of mice with purified preparations of Pnup type 23F induced antigen-specific IgM responses in sera. Interestingly, oral immunization of as little as 10 μg of Pnup type 23F was sufficient to induce systemic IgM responses. Pnup-specific IgM antibodies peaked by day 7 and no booster responses were evident after a second dose on day 14. In order to examine whether IgG and IgA Pnup-specific immune responses are induced by mucosal immunization, the mucosal adjuvant CT was mixed with Pnup type 23 as an oral vaccine. Co-oral administration of CT and Pnup type 23F resulted in the induction of Pnup-specific faecal IgA antibodies. These results were confirmed by detecting antigen-specific IgA-spotforming cells in mononuclear cell suspensions prepared from the intestine of immunized mice. These findings suggest that oral immunization with Pnup in the presence of mucosal adjuvants, such as CT, could induce Pnup-specific IgA responses whereas Pnup alone did not. In an attempt to further enhance antigen-specific antibody responses, Pnup type 23F was encapsulated in liposomes and used as mucosal vaccine. However, immunogenicity of Pnup was not improved.
  • Ichiro Takahashi, Hiroshi Kiyono, Raymond J. Jackson, Kohtaro Fujihashi, Herman F. Staats, Shigeyuki Hamada, John D. Clements, Kenneth L. Bost, Jerry R. McGhee
    Infection and Immunity 64(4) 1290-1298 1996年  
    Linear B- and T-cell epitopes spanning all 103 amino acids of the Escherichia coli heat-labile toxin B subunit (LT-B) were assessed in mice orally immunized with native LT or with recombinant Salmonella enteritidis expressing LT-B. Oral administration of native LT induced mucosal immunoglobulin A (IgA) antibodies reactive with an epitope at residues 85 to 91, while IgA induced by recombinant Salmonella LT-B reacted with an epitope at residues 36 to 44. Serum IgG anti-LT-B antibodies from mice orally immunized with either LT or with recombinant Salmonella LT-B were directed to both epitopes. A single T-cell epitope spanning residues 34 to 42 was identified by T-cell proliferative and cytokine responses. When n 20-mer peptide (residues 26 to 45) with B- and T-cell epitopes was given orally to BALB/c (H-2(d)) and B10 congenic (I-A(d), I-Ab, and I-A(k)) mice, significant fecal IgA and serum IgG anti-LT-B antibodies were induced. The peptide also induced LT-B-specific T-cell proliferative responses in these mice. Orally administered LT-B peptide (residues 26 to 45) induced a cytokine profile indicative of both T helper 1- and 2-type cells. The remarkable immunogenicity of this 20-mer peptide makes it a candidate for a vaccine to protect against enterotoxigenic E. coli.
  • J. Infect. Dis. 155 : 627-635. 173(3) 627-635 1996年  
  • SD Simpson, DP Snider, LA Zettel, H Kiyono, JC Unkeless, PB Ernst
    CELLULAR IMMUNOLOGY 167(1) 122-128 1996年1月  
    IgA and IgG binding factors (BF) can be found in the supernatant (T-h SUP) Of cultures containing macrophages and CD4(+) T cells stimulated with particulate antigens such as SRBC. Previous work indicated that these IgBF, when mixed with normal serum immunoglobulin, could block the activity of suppressor T cells (T-s) and allow IgA and IgG PFC responses in vibro. We present serologic and functional evidence that IgABF and IgGBF in T-h sup are soluble Fc alpha R and Fc gamma RII(or III), respectively. Th sup adsorbed on affinity columns containing anti-Fc gamma RII/III mAb or murine IgG failed to augment IgG PFC responses. Material eluted from either the IgG or anti-Fc gamma RII/ III columns could be added back, interchangeably, to the adsorbed T-h sup and restore IgG PFC. Recombinant murine Fc gamma RII (rFc gamma RII), added to the same adsorbed T-h sup at 0.01 to 0.5 ng/ml, resulted in a similar augmentation of IgG PFC. Interestingly, much higher concentrations of rFc gamma RII (10-100 ng/ ml) could not, augment IgG; PPC responses. Protein dot blots showed that T-h sup and the eluted material from murine IgG: columns contained structures reactive with the Fc gamma RII/III mAb. Similar studies using purified Fc alpha R revealed that IgABF eluted from IgA or anti-Fc alpha R columns was in fact Fc alpha R. Cross-adsorption studies indicated clearly that the IgGBF (Fc gamma RII/III) and the IgABF (FC alpha R) were separate molecules produced in the same T-h sup and that each regulated their respective Ig isotype independently. Thus, cultures of splenic macrophage and CD4(+) T cells, in the presence of particulate antigens such as SRBC, generate both Fc gamma RII/III and Fc alpha R. This soluble FcR in combination with serum Ig act to block isotype-specific T-s cells at low concentration in vitro. (C) 1996 Academic Press, Inc.
  • John L. VanCott, Toshiya Kobayashi, Masafumi Yamamoto, Subramonia Pillai, Jerry R. McGhee, Hiroshi Kiyono
    Vaccine 14(5) 392-398 1996年  
    Liposome and cholera toxin (CT) are considered to be effective antigen delivery vehicles and adjuvants for mucosal vaccines. The effect of these antigen delivery systems on adjuvant responses to mucosally administered pneumococcal polysaccharide (Pnup) was investigated in this study. Both mucosal (e.g oral) and systemic (IP) immunization of mice with purified preparations of Pnup type 23F induced antigen-specific IgM responses in sera. Interestingly, oral immunization of as little as 10 μg of Pnup type 23F was sufficient to induce systemic IgM responses. Pnup-specific IgM antibodies peaked by day 7 and no booster responses were evident after a second dose on day 14. In order to examine whether IgG and IgA Pnup-specific immune responses are induced by mucosal immunization, the mucosal adjuvant CT was mixed with Pnup type 23 as an oral vaccine. Co-oral administration of CT and Pnup type 23F resulted in the induction of Pnup-specific faecal IgA antibodies. These results were confirmed by detecting antigen-specific IgA-spotforming cells in mononuclear cell suspensions prepared from the intestine of immunized mice. These findings suggest that oral immunization with Pnup in the presence of mucosal adjuvants, such as CT, could induce Pnup-specific IgA responses whereas Pnup alone did not. In an attempt to further enhance antigen-specific antibody responses, Pnup type 23F was encapsulated in liposomes and used as mucosal vaccine. However, immunogenicity of Pnup was not improved.
  • 清野宏, 広井隆親, 山本正文, 藤橋浩太郎
    日本免疫学会総会・学術集会記録 25 106 1995年10月  
  • 藤橋浩太郎, 山本正文, 清野宏
    日本免疫学会総会・学術集会記録 25 256 1995年10月  
  • 清野 宏, 廣井 隆親, 山本 正文, 藤橋 浩太郎
    歯科基礎医学会雑誌 37 1995年8月10日  
  • FW VANGINKEL, CG LIU, JW SIMECKA, JY DONG, T GREENWAY, RA FRIZZELL, H KIYONO, MCGHEE, JR, DW PASCUAL
    HUMAN GENE THERAPY 6(7) 895-903 1995年7月  
    One major concern about using adenoviral vectors for repetitive gene delivery to lung epithelial cells is the induction of an immune response to the vector, thus, impeding effective gene transduction. To assess the immune response to the adenoviral vector, repetitive intratracheal (i.t.) gene dosing was performed in CD-1 mice using the replication-deficient adenovirus 5 (Ade5) vector carrying the lacZ gene, and compared to the antibody responses induced by conventional intranasal (i.n.) and intraperitoneal (i.p.) routes of immunization. Kinetics of serum IgG, IgA, and IgM antibody responses to the adenoviral vector and to beta-galactosidase (beta-Gal) were evaluated. Two or three adenoviral vector doses given by i.t., i.n., or i.p. routes resulted in serum IgG titers in excess of 1:200,000, whereas serum IgM and IgA were moderately induced. Analysis of the predominant murine IgG subclass was determined to be IgG(2b) and IgG(2a). To determine the localization of this antibody response, the ELISPOT assay was employed. Lymphocytes were isolated from the lung, the lower respiratory lymph nodes (LRLN), the nasal passages (NP), and the spleen. For i.t- and i.n.-administered mice, the highest IgA spot-forming cell (SFC) response to Ade5 and beta-Gal was located in the NP and in the lung. Both the lung and the LRLN showed elevated numbers of IgG SFCs (4- to 12-fold greater than splenic IgG SFC response) for Ade5 and beta-Gal. This evidence suggests that the lung and associated lymphoid tissues were the source for serum antibodies. Further analysis of serum antibodies showed that the i.p.- and i.t.-administered groups yielded the greatest neutralization titers to Ade5, suggesting that the reduced effectiveness of repetitive gene transfer is in part due to circulating neutralizing antibodies. Thus, repetitive i.t. instillation will stimulate a localized and systemic antibody response to the vector.
  • RJ JACKSON, K FUJIHASHI, H KIYONO, MCGHEE, JR
    FASEB JOURNAL 9(3) A215-A215 1995年3月  
  • Ichiro Takahashi, Ichiro Nakagawa, Hiroshi Kiyono, Jerry R. McGhee, John D. Clements, Shigeyuki Hamada
    Biochemical and Biophysical Research Communications 206(1) 414-420 1995年1月5日  
    Heat-labile enterotoxin (LT) from enterotoxigenic Escherichia coli is known to possess strong immunoregulatory potential in terms of inhibition of the induction of oral tolerance and adjuvanticity in oral immunization. We found that oral administration of an immunogenic peptide of LT [LT-B(26-45) spanning the residues 26-45 of LT-B] induced systemic unresponsiveness in BALB/c mice resulting in diminished serum IgG responses. It was also shown that the spleen (SP) CD4+ T cells of tolerized mice failed to proliferate, whereas the Peyer′s patches (PP) CD4+ T cells responded to the peptide. RT-PCR revealed that the SP CD4+ T cells did not generate IL-2 mRNA, while the PP CD4+ T cells expressed significant levels of IFN-γ, IL-2, IL-4, and TGF-β mRNA. Adoptive transfer of LT-B-specific intraepithelial lymphocytes to the tolerant mice abrogated the tolerance. In the reversed mice, LT-B(26-45)-stimulated SP CD4+ T cells expressed significant levels of IFN-γ, IL-2, IL-4, and IL-6 mRNA. These results indicate that PP CD4+ T cells induce oral tolerance due to systemic T cell anergy. © 1995 Academic Press, Inc.
  • Ichiro Takahashi, Ichiro Nakagawa, Hiroshi Kiyono, Jerry R. McGhee, John D. Clements, Shigeyuki Hamada
    Biochemical and Biophysical Research Communications 206(1) 414-420 1995年1月5日  
    Heat-labile enterotoxin (LT) from enterotoxigenic Escherichia coli is known to possess strong immunoregulatory potential in terms of inhibition of the induction of oral tolerance and adjuvanticity in oral immunization. We found that oral administration of an immunogenic peptide of LT [LT-B(26-45) spanning the residues 26-45 of LT-B] induced systemic unresponsiveness in BALB/c mice resulting in diminished serum IgG responses. It was also shown that the spleen (SP) CD4+ T cells of tolerized mice failed to proliferate, whereas the Peyer′s patches (PP) CD4+ T cells responded to the peptide. RT-PCR revealed that the SP CD4+ T cells did not generate IL-2 mRNA, while the PP CD4+ T cells expressed significant levels of IFN-γ, IL-2, IL-4, and TGF-β mRNA. Adoptive transfer of LT-B-specific intraepithelial lymphocytes to the tolerant mice abrogated the tolerance. In the reversed mice, LT-B(26-45)-stimulated SP CD4+ T cells expressed significant levels of IFN-γ, IL-2, IL-4, and IL-6 mRNA. These results indicate that PP CD4+ T cells induce oral tolerance due to systemic T cell anergy. © 1995 Academic Press, Inc.
  • MCGHEE, JR, M MARINARO, RJ JACKSON, TAKAHASHI, I, T HIROI, S CHATFIELD, J VANCOTT, D PASCUAL, F VANGINKLE, K FUJIHASHI, M YAMAMOTO, J CLEMENTS, K BOST, H KIYONO
    JOURNAL OF CELLULAR BIOCHEMISTRY 166-166 1995年1月  
  • IN MBAWUIKE, S DIFABIO, K FUJIHASHI, H KIYONO, MCGHEE, JR, RB COUCH
    JOURNAL OF CELLULAR BIOCHEMISTRY 304-304 1995年1月  
  • Hiroki Bukawa, Ken-Ichiro Sekigawa, Kenji Hamajima, Jun Fukushima, Yoshihiko Yamada, Hiroshi Kiyono, Kenji Okuda
    Nature Medicine 1(7) 681-685 1995年  
    Control of pandemic infection of human immunodeficiency virus type 1 (HIV-1) requires some means of developing mucosal immunity against HIV-1 because sexual transmission of the virus occurs mainiy through the mucosal tissues. However, there is no evidence as yet that the secretory immunoglobulin A (IgA) antibody induced by immunization with antigens in experimental animals can neutralize HIV-1. We demonstrate here that oral immunization with a new macromolecular peptide antigen and cholera toxin (CT) induces a high titre (1:211) of gut-associated and secretory igA antibody to HIV-1. Using three different neutralizing assays, we clearly demonstrate that this secretory igA antibody is able to neutralize HIV-1Hib, HIVSF2and HIV-1MN. Our new approach may prove to be important in the development of a mucosal vaccine that will provide protection of mucosal surfaces against HIV-1. © 1995 Nature Publishing Group.

共同研究・競争的資金等の研究課題

 12